CLASS II ONGOING Device recall · Reported 7 Sep 2022 · FDA Enforcement Report

therascreen Fgfr Rgq Rt-pcr Kit (CE Ivd recalled by Qiagen Sciences

Qiagen Sciences is recalling therascreen Fgfr Rgq Rt-pcr Kit (CE Ivd, not, distributed in Indiana, Minnesota, North Carolina, Texas. The recall was initiated on 20 Jul 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot number: 172017804 Exp Date: 10.11.2022 169046610 Exp. Date: 12.06.2022
Quantity recalled29 kits

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1651-2022
FDA event ID
90691
Recalling firm
Qiagen Sciences, Germantown, MD
Classification
Class II
Status
Ongoing
Recall initiated
20 Jul 2022
FDA classified
29 Aug 2022
Reported
7 Sep 2022
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Other Reasons

Timeline

20 Jul 2022Recall initiated by company
29 Aug 2022Classified by FDA+40 days
7 Sep 2022Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Increased occurrence rate of false positive results, lead to a false positive sample result that could subsequently be incorrectly reported from the laboratory. A false positive result could lead to the risk of the patient being exposed to an inappropriate or suboptimal anti-cancer treatment and/or unnecessarily experiencing side effects

Product as listed by the FDA

therascreen FGFR RGQ RT-PCR Kit (CE IVD, not sold in the US) REF 874711

Where it was distributed

IN, NC, MN, TX Foreign: Belgium, China, Germany, Jordan, Italy, Netherlands, Malaysia, Spain, Thailand

IndianaMinnesotaNorth CarolinaTexas

Questions about this recall

Why was it recalled?

Increased occurrence rate of false positive results, lead to a false positive sample result that could subsequently be incorrectly reported from the laboratory. A false positive result could lead to the risk of the patient being exposed to an inappropriate or suboptimal anti-cancer treatment and/or unnecessarily experiencing side effects

Which lots are affected?

Lot number: 172017804 Exp Date: 10.11.2022 169046610 Exp. Date: 12.06.2022

Where was it sold?

IN, NC, MN, TX Foreign: Belgium, China, Germany, Jordan, Italy, Netherlands, Malaysia, Spain, Thailand

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

2 other products · FDA event 90691

This product is part of a recall event; the main page for the event is Fgfr Rgq Rt-pcr Kit (Ruo, not Ivd) recalled by Qiagen Sciences.

More recalls from Qiagen Sciences

All 23

Other Test Kits & Diagnostics recalls

All 2,656